[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sarcopenia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sarcopenia":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,210,0,25,[9,43,81,111,142,164,197,221,246,265,297,319,345,374,397,425,448,479,505,536,558,584,602,632,653],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100053762","morphological-and-functional-biomarkers-of-skeletal-muscle-adaptations-in-sarcopenia-100053762",false,"NCT07692308","Morphological and Functional Biomarkers of Skeletal Muscle Adaptations in Sarcopenia","Morphological and Functional Biomarkers of Skeletal Muscle Adaptations for Early Detection of Sarcopenia and of the Therapeutic Effects of a Home-Based Exercise Intervention: A Randomized-Controlled Trial","EXEDOS","Inclusion Criteria:\n\n* Sedentary individuals aged over 50 years.\n* Individuals with sarcopenia, defined as reduced muscle mass assessed by bioelectrical impedance analysis and reduced muscle strength assessed by handgrip strength, according to EWGSOP2 criteria.\n* Individuals at risk of sarcopenia, defined as reduced muscle mass with preserved muscle strength.\n* Healthy age-, sex-, and physical activity-matched older adults eligible for inclusion in the reference cohort.\n* Ability to understand the study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* Hospitalization within the previous 6 weeks.\n* Substance or alcohol abuse.\n* Use of medications that may impair balance or coordination.\n* Major locomotor impairments.\n* Inability to complete the exercise protocol.\n* Medical, cognitive, or functional conditions that, in the opinion of the investigators, may interfere with safe participation, adherence to the study procedures, or completion of the follow-up assessments.",true,"ALL","50 Years",{"count":22,"type":23},192,"ESTIMATED","INTERVENTIONAL",[26],"NA","Sarcopenia is an age-related condition characterized by progressive loss of skeletal muscle mass, muscle strength, and physical performance. It is associated with frailty, falls, disability, reduced independence, lower quality of life, and increased healthcare burden. Despite its clinical relevance, sarcopenia remains underdiagnosed, partly because current diagnostic approaches may be difficult to implement broadly in clinical practice and may not fully capture early changes in muscle quality and neuromuscular function.\n\nThe EXEDOS study aims to evaluate an integrated diagnostic and therapeutic strategy for the early detection and management of sarcopenia. The study will assess Quantitative Ultrasound with Radio-Frequency analysis (QUS-RF) as a non-invasive, accessible, and radiation-free tool to characterize muscle morphology, microstructure, and quality. QUS-RF-derived parameters will be compared with established assessments, including body composition, muscle strength, physical performance, and imaging-based measures, to determine their feasibility, reliability, diagnostic accuracy, and responsiveness to change.\n\nThe study also includes a 48-week randomized, parallel-group, open-label superiority trial designed to evaluate the effects of a digitally delivered home-based exercise intervention in older adults with sarcopenia or at risk of sarcopenia. Eligible participants will be randomized to either an experimental group receiving a structured home-based exercise program or a control group receiving general physical activity recommendations in line with current guidelines. The exercise program will combine progressive resistance and aerobic training and will be supported by a digital platform allowing remote monitoring, feedback, and supervision. All participants will receive general nutritional advice.\n\nAssessments will be performed at baseline, Week 12, and Week 48. The primary outcome of the randomized trial will be the change in 30-second Chair Stand Test performance, used as an indicator of lower-limb muscle function. Secondary outcomes will include handgrip strength, lower-limb maximal and explosive strength, walking capacity, balance, body composition, QUS-RF-derived muscle parameters, quality of life, mood, physical activity, dietary indicators, blood biomarkers, adherence to the intervention, and safety. A health economic analysis will also be conducted to estimate the potential cost-effectiveness and cost-utility of the proposed diagnostic and therapeutic strategy.\n\nBy combining innovative muscle assessment with a scalable digitally supported exercise intervention, the EXEDOS study aims to improve early sarcopenia detection, personalize exercise prescription, and support the development of sustainable strategies to preserve muscle function and independence in older adults.",[29],"Sarcopenia","RECRUITING","2026-07-09",{"date":33,"type":34},"2026-07-13","ACTUAL",{"date":36,"type":34},"2026-06-03",{"date":38,"type":23},"2029-06-03",{"name":40,"class":41},"I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio","OTHER",1,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":19,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":24,"phases":55,"briefSummary":56,"conditions":57,"keywords":63,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":80},"100620841","myokine100-system-closed-loop-electrical-muscle-stimulation-to-mitigate-icu-acquired-weakness-in-medical-icu-patients-100620841","NCT07362862","MyokinE100 System: Closed Loop Electrical Muscle Stimulation to Mitigate ICU Acquired Weakness in Medical ICU Patients","Safety and Feasibility of the MyokinE100 System in ICU Settings to Mitigate ICU Acquired Weakness","ICUAW","Inclusion Criteria:\n\n* Admitted to ER or ICU within the previous 48 hours\n* APACHE II score ≥ 13\n* Meets the criteria for sepsis or severe sepsis\n* Baseline Clinical Frailty Scale (CFS) ≤ 4\n\nExclusion Criteria:\n\n* Anticipated transfer to an ICU not participating in this study\n* Expected length of ICU stay \\\u003C 48 hours\n* Myopathies (e.g. congenital)\n* Acquired myopathies with CK levels 5-times above the upper limit of normal\n* Unable to transfer from bed to chair at baseline\n* Moribund\n* Comfort care\n* New onset deep vein thrombosis within the previous 6-months\n* Malignancy in lower limb\n* Technical obstacles - fracture, burns, amputation\n* Open wound or skin abrasion at the garment application site\n* Pregnancy\n* Pacemaker and implantable cardioverter-defibrillator","18 Years","85 Years",{"count":54,"type":23},50,[26],"The goal of this clinical trial is to learn if a new medical device that sends electrical signals to the thigh muscles is safe and easy to use for people in the ICU (Intensive Care Unit) who are at risk of losing muscle strength. It will also explore whether this treatment can help slow down muscle weakening.\n\nThe main questions this study aims to answer are:\n\n* Do participants develop medical problems when receiving electrical muscle stimulation in the ICU?\n* Is electrical muscle stimulation a practical way to help reduce muscle weakness in critically ill patients?\n\nResearchers will compare the control group (standard of care) to the intervention group (standard of care plus 60-minute sessions of electrical muscle stimulation daily during the ICU stay) to see if the device is safe and easy to use.\n\nParticipants will:\n\n* Receive either standard of care or standard of care plus electrical muscle stimulation of the thigh muscles\n* Have their muscle strength checked during the study\n* Complete a survey three months after ICU discharge to check on their recovery",[58,59,60,61,49,29,62],"Sepsis","Critical Illness","ICU-acquired Muscle Weakness","ICU-acquired Weakness","Secondary Sarcopenia",[64,65,66,67,58,68,69],"Electrical muscle stimulation","Electrical Impedance Myography","Bioimpedance","Rehabilitation","Critical illness","ICU-acquired weakness","2026-06-26",{"date":72,"type":34},"2026-06-29",{"date":74,"type":34},"2026-05-05",{"date":76,"type":23},"2027-08-31",{"name":78,"class":79},"Health Discovery Labs","INDUSTRY",3,{"id":82,"slug":83,"hasResults":12,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":12,"sex":19,"minAge":51,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":91,"phases":4,"briefSummary":92,"conditions":93,"keywords":97,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":42},"100644834","functional-muscle-bone-incongruity-index-fkui-a-prospective-observational-study-100644834","NCT07677033","Functional Muscle-Bone Incongruity Index (FKUI): A Prospective Observational Study","Functional Muscle-Bone Incongruity Index (FKUI): Combined Evaluation of Handgrip Strength, Total Hip Bone Mineral Density, and Lumbar-Hip Bone Mineral Density Discordance in Adults Undergoing DXA","FKUI","Inclusion Criteria:\n\n* Age 18 years or older\n* Attendance at the Physical Medicine and Rehabilitation outpatient clinic\n* Scheduled to undergo routine bone mineral density assessment by DXA as part of clinical evaluation\n* Ability to perform handgrip strength testing\n* Availability of lumbar spine and total hip bone mineral density measurements suitable for analysis\n* Ability and willingness to provide written informed consent\n\nExclusion Criteria:\n\nExclusion Criteria:\n\n* Age younger than 18 years\n* Secondary causes of osteoporosis (e.g., hyperparathyroidism, Cushing syndrome, malignancy, or other conditions affecting bone metabolism)\n* History of metabolic bone disease\n* Major trauma or fracture within the previous 6 months\n* Upper extremity disorders that may significantly affect handgrip strength measurement (e.g., severe osteoarthritis, neurological disorders, major deformities)\n* DXA measurements that are technically inadequate or unsuitable for analysis\n* Refusal or inability to provide written informed consent",{"count":90,"type":23},200,"OBSERVATIONAL","The Functional Muscle-Bone Incongruity Index (FKUI) is a novel approach developed to evaluate the relationship between muscle function and bone health. This prospective observational study aims to investigate the clinical applicability of FKUI, which combines handgrip strength, total hip bone mineral density (BMD), and lumbar-hip BMD discordance. Approximately 200 adult participants undergoing routine DXA assessment will be enrolled. The study will examine whether the combined evaluation of muscle function and bone health parameters provides a more comprehensive assessment of musculoskeletal status than individual measures alone.",[94,95,29,96],"Osteoporosis","Musculoskeletal Health","Osteopenia",[98,87,99,100,101],"Functional Muscle-Bone Incongruity Index FKUI","Bone Mineral Density","Hip-Spine Discordance","Handgrip Strength","2026-06-24",{"date":104,"type":34},"2026-06-30",{"date":106,"type":34},"2026-05-01",{"date":108,"type":23},"2027-05-01",{"name":110,"class":41},"Kanuni Sultan Suleyman Training and Research Hospital",{"id":112,"slug":113,"hasResults":12,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":12,"sex":19,"minAge":119,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":91,"phases":4,"briefSummary":122,"conditions":123,"keywords":126,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":42},"100624585","clinical-relevance-of-ultrasound-based-intramuscular-fat-infiltration-assessment-in-hospitalized-older-adults-fatus-old-100624585","NCT07411547","Clinical Relevance of Ultrasound-based Intramuscular Fat Infiltration Assessment in Hospitalized Older Adults (FATUS-OLD)","Clinical Relevance of Matrix-based Ultrasound Assessment of Intramuscular Fat Infiltration in Hospitalized Older Adults (FATUS-OLD)","FATUS-OLD","Inclusion Criteria:\n\n* Age ≥ 75 years\n* Hospitalized in rehabilitation day-hospital program\n* Written informed consent\n\nExclusion Criteria:\n\n* Moderate to severe neurocognitive disorders\n* Inability to comply with study procedures","75 Years",{"count":121,"type":23},115,"Sarcopenia in older adults is associated not only with loss of muscle mass but also with deterioration of muscle quality, particularly intramuscular fat infiltration. While muscle mass is commonly assessed, muscle quality remains insufficiently explored in routine clinical practice.\n\nThe FATUS-OLD study aims to evaluate the clinical relevance of a novel ultrasound-based multiparametric approach to assess intramuscular fat infiltration and muscle volume in hospitalized older adults undergoing rehabilitation. The main hypothesis is that higher intramuscular fat infiltration at baseline is associated with poorer recovery of physical performance at 6 months, independently of muscle volume.\n\nThis non-invasive, rapid, and radiation-free imaging approach could improve sarcopenia phenotyping and help identify new prognostic biomarkers for clinical follow-up and future interventional trials.",[124,29,125],"Physical Performance Decline in Older Adults","Muscle Fat Infiltration",[29,127,128,129,130,131,132],"Older adults","Muscle quality","Intramuscular fat","Ultrasound imaging","Physical performance","Geriatric rehabilitation","2026-06-23",{"date":135,"type":34},"2026-06-25",{"date":137,"type":34},"2026-05-21",{"date":139,"type":23},"2028-11-21",{"name":141,"class":41},"Nantes University Hospital",{"id":143,"slug":144,"hasResults":12,"nctId":145,"briefTitle":146,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":12,"sex":19,"minAge":149,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":91,"phases":4,"briefSummary":152,"conditions":153,"keywords":154,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":158,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":42},"100593296","evaluation-of-frailty-in-patients-with-fibrosing-interstitial-lung-diseases-prognostic-and-therapeutic-impact-100593296","NCT07004595","Evaluation of Frailty in Patients With Fibrosing Interstitial Lung Diseases: Prognostic and Therapeutic Impact","FRAPID","Inclusion Criteria:\n\n* Patient with fibrosing ILD according to the ATS\u002FERS\u002FJRS\u002FALAT 2022 criteria.\n* Patient aged ≥ 65 years.\n* Outpatient consultation (scheduled appointment in an outpatient clinic, day hospital, or weekly hospital stay).\n* French-speaking patient.\n* Patient who has received an information sheet explaining the study and has not expressed opposition to participating in this research.\n\nExclusion Criteria:\n\n* Patient under legal guardianship, curatorship, or judicial protection.\n* Cognitive disorders limiting the use of questionnaires.\n* Patient with a CT scan showing an early usual interstitial pneumonia (UIP) pattern according to the ATS\u002FERS\u002FJRS\u002FALAT 2022 classification.","65 Years",{"count":151,"type":23},100,"Fibrosing interstitial lung diseases (ILDs), with idiopathic pulmonary fibrosis being the most common form, primarily affect older individuals and have a poor prognosis, with a median survival of 3 to 5 years. While antifibrotic treatments such as nintedanib and pirfenidone can slow disease progression, their efficacy is often limited by side effects, particularly in elderly patients. A comprehensive patient assessment, including evaluations of frailty and sarcopenia, could optimize care by identifying those at risk for poor outcomes or poor treatment tolerance. Frailty, characterized by reduced physiological reserves, and sarcopenia, defined as a loss of muscle mass and strength, are both associated with increased mortality and morbidity risks. Although their individual impacts on fibrosing ILDs have been documented, the combined effect of these two syndromes on patient prognosis remains unexplored, highlighting the need for further studies to guide therapeutic decision-making.",[29],[155,156,157],"Fibrosing interstitial lung diseases;","frailty","sarcopenia",{"date":102,"type":34},{"date":160,"type":34},"2025-07-20",{"date":162,"type":23},"2027-12-20",{"name":141,"class":41},{"id":165,"slug":166,"hasResults":12,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":12,"sex":19,"minAge":51,"maxAge":149,"enrollmentInfo":172,"targetDuration":4,"studyType":24,"phases":174,"briefSummary":175,"conditions":176,"keywords":179,"overallStatus":188,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":42},"100644025","the-simplified-total-body-resistance-exercise-for-muscular-hypertrophy-for-diabetic-population-d-storm-100644025","NCT07664501","The Simplified Total-body Resistance Exercise for Muscular Hypertrophy for Diabetic Population (D-STORM)","The Simplified Total-body Resistance Exercise for Muscular Hypertrophy for Diabetic Population (D-STORM): Rationale and Study Protocol for a Randomized Controlled Trial","D-STORM","Inclusion Criteria:\n\n* Aged 18 to 65 years\n* Confirmed diagnosis of Type 2 Diabetes Mellitus\n* HbA1c between 6.5% and 13.0%\n* Not currently on insulin therapy\n* Has a primary care provider\n\nExclusion Criteria:\n\n* Age below 18 or above 65 years\n* Blood pressure 160\u002F100 mmHg or higher at screening\n* HbA1c below 6.5% or above 13.0%\n* Currently on insulin therapy\n* Pregnant or planning to become pregnant within the next 6 months\n* Serious medical conditions that would prevent safe participation in an exercise programme\n* Any physical or functional limitation that would prevent participation in resistance training\n* Underlying conditions that would not allow safe participation in the exercise intervention",{"count":173,"type":23},56,[26],"Type 2 diabetes is associated with progressive loss of muscle mass, which worsens blood sugar control and increases the risk of heart disease and disability. Resistance training (weight training) has been shown to build muscle and improve blood sugar levels, but most existing programmes use high intensities that are difficult for older or inactive people with diabetes to sustain.\n\nThis study tests a new resistance training programme called D-STORM (Simplified Total-body Resistance Exercise for Muscular Hypertrophy for Diabetic Population), which uses a lower, more manageable training load designed to be safe, tolerable, and effective for adults with Type 2 diabetes who are not on insulin.\n\nParticipants will be randomly assigned to either twice-weekly D-STORM training plus their usual diabetes care, or usual care alone, for 12 weeks. The main outcome measured is change in HbA1c (a blood test reflecting average blood sugar over 3 months). Body composition, walking capacity, blood pressure, heart rate, and quality of life will also be measured.",[177,29,178],"Type 2 Diabetes Mellitus (T2DM)","Insulin Resistance",[180,181,182,183,184,185,186,187],"Type 2 diabetes mellitus","Resistance training","Muscular hypertrophy","Glycaemic control","HbA1c","Cardiometabolic outcomes","Randomised controlled trial","Minimal effective dose","NOT_YET_RECRUITING","2026-06-22",{"date":135,"type":34},{"date":192,"type":23},"2027-01-01",{"date":194,"type":23},"2027-12-31",{"name":196,"class":41},"Universiti Teknologi Mara",{"id":198,"slug":199,"hasResults":12,"nctId":200,"briefTitle":201,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":18,"sex":19,"minAge":51,"maxAge":4,"enrollmentInfo":203,"targetDuration":4,"studyType":91,"phases":4,"briefSummary":205,"conditions":206,"keywords":209,"overallStatus":188,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":214,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":42},"100633808","muscle-aging-phenotypes-in-childhood-cancer-survivors-100633808","NCT07531498","Muscle Aging Phenotypes in Childhood Cancer Survivors","Inclusion Criteria:\n\n* Age 18 years old or older at time of consent and enrolled in SJLIFE.\n* Participant (100 per group for a total of 400) is\u002Fhas:\n* Group 1: No cancer history\n* Group 2: Age and sex specific relative lean mass z-score of less than -0.5 OR age and sex specific hand grip or isokinetic (60 degrees\u002Fsec) quadriceps strength z-score of \\\u003C-0.5 AND exposure to a peripheral neurotoxin.\n* Group 3: Age and sex specific relative lean mass z-score of less than -0.5 OR age and sex specific hand grip or isokinetic (60 degrees\u002Fsec) quadriceps strength z-score of \\\u003C-0.5 AND NOT exposed to a peripheral neurotoxin.\n* Group 4: Age and sex specific relative lean mass z-score of less than -0.5 AND age and sex specific hand grip strength or isokinetic (60 degrees\u002Fsec) quadriceps strength z-score of \\\u003C-0.5 REGARDLESS of exposure status.\n* Participant or legal guardian is able and willing to give informed consent.\n\nExclusion Criteria:\n\n* Presence of implanted medical devices or metal that would interfere with MRI or MRS.\n* Female Participant is pregnant.\n* Body weight exceeding 300 pounds, due to MRI restrictions.\n* Inability to lie flat on his\u002Fher back for 90 minutes or longer for MRI.\n* Inability or unwillingness of research participant or legal guardian\u002Frepresentative to give written informed consent.",{"count":204,"type":23},533,"Childhood cancer survivors experience premature declines in muscle mass, strength, and physical function that contribute to morbidity and early mortality. The biological mechanisms driving these impairments are heterogeneous and poorly understood. This observational study aims to characterize distinct muscle health endotypes in adult survivors of childhood cancer using advanced imaging, neuromuscular testing, and functional assessment. Survivors with reduced muscle health and community controls will undergo multimodal magnetic resonance imaging and spectroscopy, nerve conduction studies, surface electromyography, body composition assessment, and physical performance testing during a single study visit integrated into an ongoing cohort evaluation. Identifying mechanistic endotypes of impaired muscle health will support development of targeted interventions to preserve function and improve long-term outcomes in childhood cancer survivors.\n\nPrimary Objective:\n\n\\- Characterize reduced muscle health endotypes in childhood cancer survivors.\n\nSecondary Objective:\n\n\\- Identify specific treatment and lifestyle related risk factors for each reduced muscle health endotype.\n\nExploratory Objective:\n\n\\- Host germline genetics will be associated with specific muscle endotypes.",[207,208,29],"Muscle Weakness","Low Muscle Mass",[210,211,212,213],"Childhood Cancer Survivors","Adult Survivors of Childhood Cancer","Neuromuscular Function","Muscle Health",{"date":133,"type":34},{"date":216,"type":23},"2026-10-01",{"date":218,"type":23},"2031-05",{"name":220,"class":41},"St. Jude Children's Research Hospital",{"id":222,"slug":223,"hasResults":12,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":227,"eligibilityCriteria":228,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":52,"enrollmentInfo":229,"targetDuration":4,"studyType":24,"phases":231,"briefSummary":232,"conditions":233,"keywords":234,"overallStatus":188,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":4},"100644034","clinical-trial-to-evaluate-the-efficacy-of-neuromuscular-electrical-stimulation-therapy-in-patients-with-sarcopenia-100644034","NCT07668258","Clinical Trial to Evaluate the Efficacy of Neuromuscular Electrical Stimulation Therapy in Patients With Sarcopenia","A Single-Center, Randomized, Double-Blind, Sham-Controlled Clinical Trial to Evaluate the Efficacy of Neuromuscular Electrical Stimulation Therapy for Improving Lower-Limb Strength and Physical Performance in Patients With Sarcopenia","NMES","Inclusion Criteria:\n\n1. Diagnosed with sarcopenia according to the Asian Working Group for Sarcopenia (2019) criteria\n2. Able to perform the exercise program provided by the investigators, with sufficient physical and cognitive function\n3. Able to understand the study explanation and provide voluntary informed consent\n4. Able to operate a mobile phone independently or with assistance from a caregiver\n\nExclusion Criteria:\n\n1\\) History of Knee Surgery\n\n* Any prior surgical procedure on either knee (right or left) 2) Recent Knee Injection or Procedure\n* Receipt of any injection or interventional procedure in either knee within the past 3 months 3) Ongoing Treatment for Knee Pain\n* Currently receiving medication or physical therapy for knee pain 4) Implanted Electrical Devices\n* Presence of an implanted electrical device (e.g., pacemaker, electrical stimulator) 5) Seizure Disorder\n* Current or past history of seizures requiring medication 6) Severe Peripheral Arterial Disease\n* Significant arterial circulatory disorder in the lower extremities 7) Hernia\n* Presence of abdominal or inguinal hernia 8) Difficulty Operating Devices\n* Difficulty operating medical devices or mobile phones 9) Metal Allergy\n* Known metal allergy that interferes with device application 10) Skin Lesions on Thigh\n* Skin conditions on the thigh (e.g., burns, scars) that interfere with electrical stimulation 11) Suspected Infection on Thigh\n* Signs suggestive of infection on the thigh (e.g., erythema, warmth) 12) Impaired Sensation at Patch Site\n* Reduced sensation at the patch site preventing adequate self-reporting 13) End-stage Organ Failure\n* Diagnosis of end-stage heart failure or end-stage renal disease requiring dialysis 14) Abnormal Laboratory Findings\n* Any of the following (based on the most recent test within 6 months; if unavailable, a screening CBC will be performed):\n\n  * Platelet count \\\u003C 50,000\u002FμL\n  * Hemoglobin \\\u003C 8.0 g\u002FdL\n  * Absolute neutrophil count \\\u003C 1,000\u002FμL 15) Impaired Ambulation\n* Difficulty walking due to visual impairment, fracture, severe muscle paralysis, dizziness, or other causes 16) Inability to Participate in Rehabilitation Exercise\n* Judged by the investigator as unable to participate in rehabilitation exercise For example, diagnosis of Cachexia, defined as: Unintentional weight loss ≥ 5% within the past 6 months, or BMI \\\u003C 20 kg\u002Fm² with ≥ 2% weight loss 17) Withdrawal or Lack of Consent 18) Other Reasons\n* Any other condition deemed by the investigator to make the participant unsuitable for participation in this clinical trial",{"count":230,"type":23},40,[26],"The goal of this clinical trial is to exploratorily evaluate the safety and efficacy of a home-based lower extremity muscle strengthening and physical performance enhancement program using Neuromuscular Electrical Stimulation (NMES) devices.\n\nParticipants will apply NMES stimulation to both thighs for 8 weeks, at a frequency of at least 4 times per week.",[29],[157,235,236,237],"muscle mass","knee strength","Physical Performance","2026-06-21",{"date":135,"type":34},{"date":241,"type":23},"2026-06-09",{"date":243,"type":23},"2027-02",{"name":245,"class":79},"Exosystems",{"id":247,"slug":248,"hasResults":12,"nctId":249,"briefTitle":250,"officialTitle":251,"acronym":4,"eligibilityCriteria":252,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":52,"enrollmentInfo":253,"targetDuration":4,"studyType":24,"phases":255,"briefSummary":256,"conditions":257,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":258,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":264},"100617496","evaluation-of-safety-and-efficacy-of-a-digital-therapeutic-device-to-improve-strength-in-sarcopenia-sarc-dtx-100617496","NCT07319377","Evaluation of Safety and Efficacy of a Digital Therapeutic Device to Improve Strength in Sarcopenia (Sarc-DTx)","A Multicenter, Prospective, Randomized, Parallel-Group, Double-blinded, Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of a Digital Therapeutic Device for Improving Muscle Strength in Patients With Sarcopenia","Inclusion Criteria\n\n* Individuals diagnosed with sarcopenia according to both the European Working Group on Sarcopenia in Older People (EWGSOP) criteria and the Asian Working Group for Sarcopenia 2019 (AWGS 2019) criteria\n* Individuals with reduced muscle strength, defined as at least one of the following:\n* Handgrip strength \\\u003C 28 kg for men or \\\u003C 18 kg for women\n* Five-times Sit-to-Stand Test time \\> 12 seconds without arm support\n* Individuals with reduced muscle mass, defined as at least one of the following:\n* Skeletal Muscle Mass Index (SMI) \\\u003C 7.0 kg\u002Fm² for men or \\\u003C 5.4 kg\u002Fm² for women measured by DXA\n* Skeletal Muscle Mass Index (SMI) \\\u003C 7.0 kg\u002Fm² for men or \\\u003C 5.7 kg\u002Fm² for women measured by BIA\n* Individuals able to independently perform sit-to-stand movements\n* Individuals with sufficient physical and cognitive capacity to participate in the exercise program\n* Individuals able and willing to provide written informed consent\n* Individuals able to operate a mobile phone independently or with assistance from a caregiver\n\nExclusion Criteria\n\n* Individuals with cognitive impairment, defined as a Mini-Mental State Examination (MMSE) score \\\u003C 20, or those unable to participate due to cognitive decline\n* Individuals with an implanted cardiac pacemaker or other implanted electronic medical device\n* Individuals with uncontrolled cardiovascular disease despite appropriate medical management\n* Individuals who have undergone lower-limb surgery within the past 6 months and are unable to ambulate independently\n* Individuals with moderate-to-severe musculoskeletal pain or functional limitations that interfere with objective functional assessments\n* Individuals with severe obesity, defined as a body mass index (BMI) \\> 50 kg\u002Fm²\n* Individuals currently receiving active cancer treatment or experiencing severe systemic frailty\n* Individuals with hemiplegia that prevents participation in the prescribed exercise program\n* Individuals who are anticipated by the investigator to be unable to complete the study procedures or follow-up assessments\n* Individuals unable to understand or comply with study instructions provided in Korean\n* Individuals considered unsuitable for study participation at the discretion of the investigator for any other reason",{"count":254,"type":23},130,[26],"This clinical trial aims to demonstrate that the use of a digital therapeutic device (exoDTx) in patients with sarcopenia is superior to self-exercise in terms of muscle strength improvement and safety.",[29],{"date":135,"type":34},{"date":260,"type":34},"2025-11-28",{"date":262,"type":23},"2026-12-30",{"name":245,"class":79},2,{"id":266,"slug":267,"hasResults":12,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":4,"eligibilityCriteria":271,"healthyVolunteers":18,"sex":272,"minAge":273,"maxAge":274,"enrollmentInfo":275,"targetDuration":276,"studyType":91,"phases":4,"briefSummary":277,"conditions":278,"keywords":284,"overallStatus":188,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":4},"100643860","multidimensional-determinants-of-functional-health-in-women-aged-45-60-100643860","NCT07667699","Multidimensional Determinants of Functional Health In Women Aged 45-60","Multidimensional Determinants and Structural Foundations of Functional Health In Women Aged 45-60: The Role of Muscle and Bone Health","Inclusion Criteria are:\n\n* Women aged 45 to 60 years\n* Ability to read and complete study questionnaires\n* Provision of written informed consent\n* Ability to complete physical performance assessments\n\nExclusion Criteria are:\n\n* Acute systemic illness\n* Active malignancy\n* Severe neurological or orthopedic impairment limiting physical performance assessment\n* Cognitive impairment precluding informed consent or questionnaire completion","FEMALE","45 Years","60 Years",{"count":90,"type":23},"1 Day","The goal of this observational study is to learn about the multidimensional determinants of functional health in women aged 45 to 60 years. The study will focus on the role of muscle strength, bone mineral density, body composition, physical activity, sleep quality, depressive symptoms, and menopause-related symptoms in functional health.\n\nThe main questions it aims to answer are:\n\n1. Does muscle strength contribute to functional health in women aged 45 to 60 years?\n2. Does bone mineral density contribute to functional health in women aged 45 to 60 years?\n3. How are physical activity, sleep quality, depressive symptoms, body composition, and menopause-related quality of life associated with functional health?\n\nParticipants will:\n\n* Undergo handgrip strength measurement\n* Perform a 30-second chair stand test\n* Undergo bone mineral density and body composition assessment\n* Complete questionnaires about physical activity, sleep quality, depressive symptoms, menopausal symptoms, and quality of life\n* Provide demographic and clinical information",[279,280,281,99,29,282,283],"Healthy","Perimenopausal Depression","Menopausal Complaints","Sleep Quality","Quality of Life",[285,286,287,29,282,288],"Menopause","Perimenopause","Bone mineral density","Quality of life","2026-06-19",{"date":135,"type":34},{"date":292,"type":23},"2026-06-15",{"date":294,"type":23},"2026-12-31",{"name":296,"class":41},"Kartal City Hospital",{"id":298,"slug":299,"hasResults":12,"nctId":300,"briefTitle":301,"officialTitle":301,"acronym":4,"eligibilityCriteria":302,"healthyVolunteers":18,"sex":19,"minAge":51,"maxAge":4,"enrollmentInfo":303,"targetDuration":4,"studyType":91,"phases":4,"briefSummary":305,"conditions":306,"keywords":4,"overallStatus":188,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":312,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":4},"100643884","ultrasound-assessment-of-diaphragmatic-structure-and-function-in-patients-with-liver-cirrhosis-a-point-of-care-tool-for-predicting-complications-and-sarcopenia-in-limited-resource-settings-100643884","NCT07667608","Ultrasound Assessment of Diaphragmatic Structure and Function in Patients With Liver Cirrhosis: A Point-of-Care Tool for Predicting Complications and Sarcopenia in Limited Resource Settings","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Confirmed diagnosis of liver cirrhosis based on clinical, biochemical, histological, or imaging criteria.\n3. Ability to provide written informed consent in Arabic or English.\n4. For Subgroup A: clinical indication for large-volume paracentesis with an ascitic volume of ≥5 liters.\n5. For Subgroup B: confirmed hepatic hydrothorax or confirmed absence of pleural effusion on ultrasound or chest X-ray.\n6. For Subgroup C: radiologically confirmed HCC by triphasic CT or MRI according to EASL\u002FAASLD diagnostic criteria, with available CT imaging for L3 SMI analysis.\n\nExclusion Criteria:\n\n1. Significant pre-existing primary pulmonary disease (e.g., moderate-to-severe COPD defined as FEV1\u002FFVC \\\u003C70% with FEV1 \\\u003C60% predicted, interstitial lung disease, pulmonary fibrosis) that independently affects diaphragmatic mechanics.\n2. Recent thoracic surgery, thoracocentesis within the preceding 72 hours, or thoracic trauma.\n3. Neuromuscular disease (e.g., myasthenia gravis, amyotrophic lateral sclerosis, Guillain-Barré syndrome) independently affecting diaphragmatic function.\n4. Active mechanical ventilation at time of enrollment.\n5. Pregnancy.\n6. Inability to achieve adequate ultrasound acoustic windows (e.g., due to extreme obesity or surgical dressings).\n7. Contraindications to paracentesis in Subgroup A (e.g., disseminated intravascular coagulation, bowel obstruction).\n8. Prior or planned liver transplantation within the study period, which would confound longitudinal follow-up.\n9. Refusal or inability to provide informed consent.",{"count":304,"type":23},120,"The goal of this observational study is to learn how liver cirrhosis affects the diaphragm, the main muscle used for breathing, in adults. The study will measure diaphragmatic thickness, thickening fraction, and excursion using bedside ultrasound and compare these values between patients with cirrhosis and healthy volunteers. The main questions it aims to answer are:\n\nDo patients with cirrhosis show reduced diaphragmatic function compared to healthy adults?\n\nDoes removal of ascitic fluid by paracentesis improve diaphragmatic mechanics?\n\nCan ultrasound measurements of the diaphragm serve as a reliable non-invasive marker of sarcopenia when compared to CT scans?\n\nParticipants will:\n\nUndergo diaphragmatic ultrasound during quiet and deep breathing\n\nProvide clinical and laboratory data related to liver disease severity\n\nIn some cases, have ultrasound repeated before and after paracentesis\n\nFor patients with hepatocellular carcinoma, CT scans will be analyzed to measure muscle mass",[307,308,309,310,29,311],"Cirrhosis of the Liver","Ascites","Pleural Effusion Disorder","Hepatocellular Carcinoma (HCC)","Diaphragm Movement",{"date":135,"type":34},{"date":314,"type":23},"2026-08-10",{"date":316,"type":23},"2027-12-10",{"name":318,"class":41},"Assiut University",{"id":320,"slug":321,"hasResults":12,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":325,"eligibilityCriteria":326,"healthyVolunteers":12,"sex":19,"minAge":327,"maxAge":4,"enrollmentInfo":328,"targetDuration":4,"studyType":91,"phases":4,"briefSummary":330,"conditions":331,"keywords":334,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":340,"completionDateStruct":341,"leadSponsor":343,"locationsCount":42},"100633695","sarcopenia-in-older-patients-hospitalized-for-acute-heart-failure-100633695","NCT07530029","Sarcopenia in Older Patients Hospitalized for Acute Heart Failure.","Multimodal Approach to Sarcopenia and Its Prognostic Impact in Older Patients Hospitalized for Acute Heart Failure (MUSICA Study).","MUSICA","Inclusion Criteria:\n\n* Patients with HF-pEF (LVEF ≥50%), hospitalized for AHF, with signs of fluid overload and requiring intravenous diuretic treatment. The diagnosis of HF will be made in accordance with ESC-2021 guidelines based on the presence of typical signs and symptoms, elevated natriuretic peptides (BNP \\>100 pg\u002FmL or NTproBNP \\>300 pg\u002FmL), and evidence of underlying structural heart disease by transthoracic echocardiography (performed during admission or within a period of 24 months prior to admission).\n* Age ≥ 80 years.\n* NYHA functional class II-IV.\n\nExclusion Criteria:\n\n* End-of-life care.\n* Inability to comply with study procedures.\n* Already included patients on readmission.","80 Years",{"count":329,"type":23},110,"Acute heart failure (AHF) is the leading cause of hospitalization in people over 65, with the group with preserved ejection fraction (HFpEF) being the most closely related to aging. Among its comorbidities, sarcopenia stands out, and its assessment requires measurement of muscle mass. Muscle ultrasound is an accessible and economical alternative, although its prognostic value is still uncertain. The presence of common pathophysiological mechanisms between HF-PEF and sarcopenia leads to the study of biomarkers to improve their characterization.\n\nMultimodal characterization of sarcopenia, integrating muscle mass and strength with skeletal and cardiac muscle biomarkers, will improve prognostic stratification at discharge in elderly patients with HFpEF hospitalized for ACS. We seek to evaluate the prognostic value of muscle mass estimated by ultrasound, in combination with strength measurements and circulating biomarkers related to sarcopenia, as this could improve the prediction of clinical events after hospitalization for AHF in elderly patients with HFpEF. In addition, ultrasound estimation of muscle mass will be analyzed against BIA, the relationship between skeletal and cardiac muscle will be characterized, and the usefulness of the multimodal approach to sarcopenia will be evaluated.\n\nThis study is observational, prospective, and single-center. It will include 110 patients hospitalized for AHF aged ≥80 years. Events will be monitored for 6 months after discharge. Variables include clinical data, ultrasound data (lung, VExUS, and muscle mass), congestion markers (BNP, CA125), biomarkers (GDF-15, sST2, BDNF, and myostatin\u002Ffollistatin), bioimpedance, and dynamometry. Data will be analyzed using regression models and survival analysis to identify prognostic factors.\n\nThis study has the potential to improve the clinical management of patients with acute heart failure by providing key information on its interaction with sarcopenia. The results could help identify more effective strategies to reduce rehospitalization and mortality in these patients, improving their prognosis and quality of life.",[332,29,333],"Acute Heart Failure (AHF)","Heart Failure",[332,29,335,336,337],"Point-of-care ultrasound (PoCUS)","Biomarkers","Heart Failure with Preserved Ejection Fraction","2026-06-18",{"date":133,"type":34},{"date":74,"type":34},{"date":342,"type":23},"2027-11",{"name":344,"class":41},"Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal",{"id":346,"slug":347,"hasResults":12,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":351,"eligibilityCriteria":352,"healthyVolunteers":12,"sex":19,"minAge":51,"maxAge":4,"enrollmentInfo":353,"targetDuration":4,"studyType":24,"phases":355,"briefSummary":356,"conditions":357,"keywords":362,"overallStatus":188,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":42},"100644394","the-shape-project-hospital-system-for-physical-activity-and-active-participation-after-hospitalized-decompensation-of-respiratory-chronic-diseases-100644394","NCT07663955","The SHAPE Project (Hospital System for Physical Activity and Active Participation) After Hospitalized Decompensation of Respiratory Chronic Diseases","The SHAPE Project (Hospital System for Physical Activity and Active Participation) After Hospitalized Decompensation of Respiratory Chronic Disease in Respiratory Patients","SHAPE","Inclusion Criteria:\n\n* Age 65 years or older\n* Admission at risk of functional decline (hospital admission lasting \\> 5 days) Discharge destination: Home or residence where the patient lived prior to admission\n* Favorable multidisciplinary assessment by the healthcare team responsible for the patient during admission regarding the patient's physical fitness to perform the SHAPE program\n\nExclusion Criteria:\n\n* Explicit decision by the patient not to participate\n* Musculoskeletal problem that limits mobility\n* Limiting sociopathy (socio-family environment not optimal to guarantee program adherence)\n* Drug dependence (condition at discharge not optimal to guarantee program adherence)\n* Insufficient digital literacy and\u002For lack of online resources that do not guarantee participation in telematic sessions\n* Discharge destination: Long-term convalescent care center\n* Advanced and\u002For terminal stage of lung disease (patients with the following resources activated: Home Care and Support Teams Program for advanced disease (PADES), intensive home care at discharge due to extreme frailty (AT-DOM), advanced chronic disease requiring palliative care and a life expectancy of 12 months or less (MACA))Unstable underlying non-pulmonary disease (whether medical or mental, for example: acute myocardial infarction) Recent myocardial infarction (MI), recent stroke, recent hospitalization for psychiatric decompensation\\*) \\*Recent = within the last 3 months\n* Unstable underlying pulmonary disease (vital hemoptysis, new thoracic neoplasm, high-intermediate risk pulmonary thromboembolism)",{"count":354,"type":23},90,[26],"It is widely established that a lack of adapted physical activity (APA) and sedentary behaviors increase the prevalence of frailty, which exacerbates chronic diseases. Hospital stays amplify this phenomenon, leading to physical deconditioning, often irreparable, especially in older patients if it is not detected and treated promptly. To date, there is no standard of care focused on APA to address frailty acquired during hospital stays. In this context, the SHAPE project (Hospital System for Physical Activity and Active Participation) aims to prevent dependency in older adults with chronic diseases by developing an innovative patient journey based on APA. The project seeks to reduce frailty acquired during hospital stays by establishing standards for APA prescription, based on early diagnosis and intervention. SHAPE ensures equal access to care through an accessible and user-friendly web platform, designed for older users and also including those in rural areas. It fosters the resilience of healthcare systems by integrating a preventive and multidisciplinary approach into hospital treatments and optimizes resources through a tiered care model that provides progressive and personalized care.\n\nAlthough hospital stays have been shown to trigger physical deconditioning, there is no adapted physical activity program initiated by the hospital and followed at home after hospital discharge from a severe exacerbation in patients with chronic respiratory diseases. The SHAPE Project offers a highly beneficial tool for patients with acute or exacerbated chronic respiratory disease requiring hospitalization, promoting better overall recovery after discharge. Furthermore, this project will foster healthy lifestyles and promote health from a sustainability and prevention perspective. Of particular interest is the opportunity to offer a lifestyle change program (physical activity and hygiene-dietary measures) focused on respiratory patients and adapted to their specific needs. Moreover, the project is considered innovative in implementing healthy clinical practices through telemedicine. In addition, it offers post-hospital discharge services that, to date, have not been considered in a generic way for respiratory patients except in selective subgroups (post-COVID, patients included in lung transplant program, etc.).\n\nIn respiratory patients who have required high-risk admission due to decompensation, the implementation of the SHAPE program after hospital discharge as a support program that combines an adapted physical activity plan and general hygiene and dietary advice will improve the health indicators (frailty, sarcopenia, dyspnea, exercise tolerance, quality of life) of these patients.",[358,29,359,360,361],"Frailty","Hospital Discharge","Physical Activity","Acute Exacerbation Chronic Pulmonary Disease",[363,156,157,364,365],"adapted physical activity","hospital discharge","acute exacerbation chronic pulmonary disease","2026-06-17",{"date":133,"type":34},{"date":369,"type":23},"2026-09-01",{"date":371,"type":23},"2028-03-30",{"name":373,"class":41},"Hospital Universitari de Bellvitge",{"id":375,"slug":376,"hasResults":12,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":4,"eligibilityCriteria":380,"healthyVolunteers":12,"sex":19,"minAge":274,"maxAge":4,"enrollmentInfo":381,"targetDuration":4,"studyType":24,"phases":383,"briefSummary":384,"conditions":385,"keywords":387,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":391,"startDateStruct":392,"completionDateStruct":393,"leadSponsor":395,"locationsCount":42},"100632387","effectiveness-of-rpt-with-elastic-band-in-tx-of-sarcopenia-in-ltcfs-100632387","NCT07513025","Effectiveness of RPT With Elastic Band in Tx of Sarcopenia in LTCFs","The Clinical Effectiveness of Progressive Resistance Training With Elastic Band in Postponing and Preventing Sarcopenia Among Older Adults in Rural Long-Term Care Facilities","Inclusion Criteria:\n\n1. Older adults aged 60 years or above who are either receiving daycare services at long-term care facilities affiliated with or contracted by this hospital, or residents living in the hospital-affiliated nursing home.\n2. Individuals with sufficient cognitive and physical capacity to participate in a progressive resistance training program incorporating elastic bands, with each session lasting at least 30 minutes. -\n\nExclusion Criteria:\n\n1. Inability to maintain a seated position for more than one hour.\n2. Presence of uncontrolled hypertension, recent infections, major cardiovascular diseases, or other contraindications to exercise training as defined by the American College of Sports Medicine (ACSM).\n3. Long-term bedridden individuals unable to participate in the progressive resistance training program incorporating elastic bands.\n4. Individuals with respiratory diseases requiring regular oxygen support in daily life.",{"count":382,"type":23},60,[26],"The goal of this clinical trial is to evaluate the effectiveness of progressive resistance training using elastic bands in treating and delaying the progression of sarcopenia among older adults in long-term care facilities. Sarcopenia, characterized by a progressive decline in muscle mass and strength, affects more than 20% of individuals aged over 65 in Taiwan and is a significant risk factor for impaired daily functioning, falls, and increased mortality in older adults. While resistance or aerobic exercises are known to improve muscle strength and function in the elderly, such interventions are challenging to implement long-term in rural care facilities due to limited resources.\n\nThe study aims to determine:\n\nWhether elastic band progressive resistance training can achieve clinical benefits in treating and delaying sarcopenia with minimal rehabilitation personnel.\n\nWhether this training model can be adapted to rural care facilities and other resource-limited settings, aligning with the goals of Taiwan's Long-Term Care 2.0 program.\n\nParticipants will engage in a 12-week program, involving twice-weekly, 30-minute sessions of upper and lower limb resistance training using elastic bands. The training incorporates major muscle groups and proprioceptive neuromuscular facilitation (PNF) techniques.\n\nPrimary outcomes:\n\nSkeletal muscle mass index of the limbs Dominant hand grip strength Walking speed SARC-F questionnaire scores\n\nSecondary outcomes:\n\nMaximal voluntary isometric contraction (MVIC) of the dominant hand Muscle thickness assessed via ultrasound Functional activities of the dominant upper limb Calf circumference Quality of life indicators\n\nThe study will be conducted in long-term care facilities affiliated with or contracted by the Ministry of Health and Welfare Qishan Hospital. The findings aim to provide evidence for scalable, low-resource sarcopenia interventions suitable for rural and underserved populations.",[29,386],"Long Term Care Facility",[157,388,389,390],"elastic band","progressive resistance training","long-term care facility",{"date":338,"type":34},{"date":74,"type":34},{"date":394,"type":23},"2026-09-30",{"name":396,"class":41},"Cishan Hospital, Ministry of Health and Welfare",{"id":398,"slug":399,"hasResults":12,"nctId":400,"briefTitle":401,"officialTitle":402,"acronym":4,"eligibilityCriteria":403,"healthyVolunteers":12,"sex":404,"minAge":405,"maxAge":4,"enrollmentInfo":406,"targetDuration":4,"studyType":24,"phases":408,"briefSummary":409,"conditions":410,"keywords":412,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":417,"lastUpdatePostDateStruct":418,"startDateStruct":420,"completionDateStruct":421,"leadSponsor":423,"locationsCount":42},"100628550","creatine-supplementation-and-resistance-training-to-improve-sarcopenia-parameters-in-patients-with-prostate-cancer-after-androgen-deprivation-therapy-100628550","NCT07463092","Creatine Supplementation and Resistance Training to Improve Sarcopenia Parameters in Patients With Prostate Cancer After Androgen Deprivation Therapy","The Effect of Creatine Supplementation Associated With Resistance Training on Sarcopenia Parameters and Muscle Density in Prostate Cancer Patients After Androgen Deprivation Therapy","Inclusion Criteria:\n\n* Men aged ≥ 40 years;\n* Patients with histologically or cytologically confirmed localized prostate cancer;\n* Patients who have undergone surgical castration or pharmacological castration with gonadotropin-releasing hormone (GnRH\u002FLHRH) agonists or antagonists for at least six months prior to the start of the intervention;\n* Patients receiving continuous or intermittent androgen deprivation therapy;\n* Patients with an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2;\n* Not engaged in resistance training in the three months prior to the intervention;\n* Not using creatine supplementation in the three months prior to the intervention;\n* Willing to participate in a 12-week intervention consisting of resistance training performed three times per week and daily supplementation with creatine monohydrate or maltodextrin.\n\nExclusion Criteria:\n\n* Patients with insulin-dependent diabetes mellitus;\n* Patients with dialysis-dependent renal failure;\n* Patients with severe chronic liver disease;\n* Estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin\u002F1.73 m²;\n* Any hormonal treatment outside that established by the medical team;\n* Patients planning to undergo chemotherapy within the next six months.","MALE","40 Years",{"count":407,"type":23},34,[26],"This randomized, double-blind, placebo-controlled clinical trial will investigate the effects of creatine supplementation combined with a 12-week supervised resistance training program on muscle mass, muscle strength, physical performance (e.g., parameters of sarcopenia), and muscle density in men with prostate cancer undergoing androgen deprivation therapy (ADT). ADT often causes loss of lean mass, reduced muscle strength, functional impairment, and increased fat mass. Eligible male patients will be randomly assigned to receive either creatine monohydrate or a placebo (maltodextrin) in a double-blind manner, in addition to participating in the resistance exercise program. Assessments will be performed at baseline and after the 12-week intervention period and will include:\n\n* Muscle density and architecture assessed by ultrasound\n* Body composition (lean mass and fat mass)\n* Muscle strength\n* Physical performance (functional performance tests)\n* Inflammatory biomarkers\n* Vascular function parameters\n\nThe primary goal is to assess whether creatine supplementation combined with resistance training can safely improve muscle quality and quantity, strength, and physical function in these patients. If effective and safe, the intervention could help reduce muscle loss and improve quality of life in men undergoing ADT.",[411,29],"Prostate Cancer",[411,413,414,415,416,29],"Androgen Deprivation Therapy","Creatine","Resistance Training","Muscle Density","2026-06-10",{"date":419,"type":34},"2026-06-11",{"date":106,"type":34},{"date":422,"type":23},"2029-01",{"name":424,"class":41},"University of Sao Paulo",{"id":426,"slug":427,"hasResults":12,"nctId":428,"briefTitle":429,"officialTitle":430,"acronym":431,"eligibilityCriteria":432,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":433,"targetDuration":4,"studyType":24,"phases":434,"briefSummary":435,"conditions":436,"keywords":437,"overallStatus":188,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":441,"startDateStruct":442,"completionDateStruct":444,"leadSponsor":446,"locationsCount":42},"100643264","bcw-based-resistance-training-for-community-dwelling-sarcopenia-patients-100643264","NCT07601321","BCW-Based Resistance Training for Community-Dwelling Sarcopenia Patients","Effects of a Behavior Change Wheel (BCW)-Based Resistance Exercise Program on Community-Dwelling Patients With Sarcopenia: A Randomized Controlled Trial","BCW-RES","Inclusion Criteria:\n\nMeet the diagnostic criteria for sarcopenia according to the Asian Working Group for Sarcopenia (AWGS) 2025:\n\nLow muscle mass (SMI measured by BIA): For age ≥ 65, Male \\\u003C 7.0 kg\u002Fm², Female \\\u003C 5.7 kg\u002Fm²; For age 50-64, Male \\\u003C 7.6 kg\u002Fm², Female \\\u003C 5.7 kg\u002Fm².\n\nLow muscle strength (Handgrip strength): For age ≥ 65, Male \\\u003C 28 kg, Female \\\u003C 18 kg; For age 50-64, Male \\\u003C 34 kg, Female \\\u003C 20 kg.\n\nAbility to walk independently without assistive devices.\n\nClear consciousness and stable medical condition.\n\nWillingness to participate, commit to the exercise protocol, and provide signed informed consent.\n\nProficiency in using a smartphone.\n\nExclusion Criteria:\n\n* Presence of metal implants, such as cardiac pacemakers, stents, steel plates, or artificial joints (due to BIA measurement constraints).\n\nCognitive impairment, epilepsy, other neurological disorders, or severe mental illness that prevents cooperation with the study.\n\nInability to complete the exercise intervention due to severe cardiovascular or musculoskeletal diseases.\n\nSevere organ dysfunction (e.g., heart failure), organ failure, or active infection.\n\nInability to maintain adherence or significant missing data (participants who withdraw or are lost to follow-up).",{"count":151,"type":23},[26],"The purpose of this randomized controlled trial is to evaluate the effects of a Behavior Change Wheel (BCW)-based resistance exercise program on muscle health, physical performance, and exercise adherence in community-dwelling older adults with sarcopenia. Participants will be randomly assigned to either an experimental group or a waitlist control group. The experimental group will receive a 12-week BCW-based resistance exercise intervention (twice a week) immediately. The waitlist control group will maintain their usual routine for the first 3 months for comparison, and will then cross over to receive the identical 12-week intervention. The study aims to provide an effective and ethical exercise management strategy for sarcopenic patients.",[29],[29,438,439],"Resistance Exercise","Behavior Change Wheel","2026-06-08",{"date":417,"type":34},{"date":443,"type":23},"2026-06",{"date":445,"type":23},"2026-12",{"name":447,"class":41},"Hangzhou Normal University",{"id":449,"slug":450,"hasResults":12,"nctId":451,"briefTitle":452,"officialTitle":453,"acronym":454,"eligibilityCriteria":455,"healthyVolunteers":12,"sex":19,"minAge":405,"maxAge":456,"enrollmentInfo":457,"targetDuration":4,"studyType":24,"phases":459,"briefSummary":461,"conditions":462,"keywords":464,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":472,"startDateStruct":473,"completionDateStruct":475,"leadSponsor":477,"locationsCount":80},"100643184","phase-4-branched-chain-amino-acids-for-sarcopenia-in-patients-undergoing-total-knee-arthroplasty-100643184","NCT07634523","Branched Chain Amino Acids for Sarcopenia in Patients Undergoing Total Knee Arthroplasty","The Effect of BCAA on Sarcopenia in Total Knee Arthroplasty Patients: A Multi-center, Randomized Controlled Trial","LIVACT IIT","Inclusion Criteria:\n\n1\\. Patients aged 40 to 100 years who are scheduled to undergo total knee arthroplasty.\n\nExclusion Criteria:\n\n1. Participants who used antiretroviral agents within 4 weeks before the first administration of Livact.\n2. Participants who used medications associated with fatty liver within 4 weeks before the first administration of Livact, including thiazolidinediones, sodium glucose cotransporter 2 inhibitors, amiodarone, methotrexate, tamoxifen, valproate, or corticosteroids.\n3. Participants who used branched chain amino acid products or multinutritional supplements within 4 weeks before the first administration of Livact.\n4. Participants who used pain medications other than those prescribed for total knee arthroplasty treatment within 2 weeks before the first administration of Livact.\n5. Participants with markedly decreased hepatic protein synthetic function.\n6. Participants with congenital branched chain amino acid metabolism disorders.\n7. Participants with hereditary galactose intolerance, Lapp lactase deficiency, or glucose galactose malabsorption.\n8. Participants with a history of high tibial osteotomy.\n9. Participants with neurologic diseases such as stroke or Parkinson disease.\n10. Participants with gait disturbance due to causes other than arthritis.\n11. Participants taking medication for spinal stenosis.\n12. Participants with a history of hypersensitivity to the investigational product or its components.\n13. Pregnant or breastfeeding participants.\n14. Participants planning pregnancy during the trial or who have the possibility of pregnancy but do not agree to use appropriate contraception during the trial.\n15. Participants judged by the investigator to be inappropriate for participation in the clinical trial.","100 Years",{"count":458,"type":23},140,[460],"PHASE4","This multicenter, prospective, randomized controlled trial evaluates whether postoperative administration of branched chain amino acids affects skeletal muscle mass index and sarcopenia related functional outcomes in patients undergoing total knee arthroplasty.\n\nParticipants are randomly assigned to receive Livact granules 4.15 g three times daily for 3 months after surgery or to receive standard postoperative care without branched chain amino acid administration. Skeletal muscle mass index, physical function, patient reported outcomes, laboratory findings, medication compliance, and adverse events are assessed at baseline, 5 weeks, and 15 weeks after surgery.",[29,463],"Total Knee Arthroplasty",[465,466,467,468,469,463,29,470],"Branched Chain Amino Acids","BCAA","Livact","Skeletal Muscle Mass Index","Bioelectrical Impedance Analysis","Randomized Controlled Trial","2026-06-04",{"date":241,"type":34},{"date":474,"type":34},"2025-02-06",{"date":476,"type":23},"2027-05-31",{"name":478,"class":41},"Seoul National University Hospital",{"id":480,"slug":481,"hasResults":12,"nctId":482,"briefTitle":483,"officialTitle":484,"acronym":4,"eligibilityCriteria":485,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":486,"enrollmentInfo":487,"targetDuration":4,"studyType":24,"phases":488,"briefSummary":489,"conditions":490,"keywords":493,"overallStatus":188,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":499,"startDateStruct":500,"completionDateStruct":502,"leadSponsor":503,"locationsCount":42},"100642856","silkworm-pupa-powder-improves-alzheimers-disease-100642856","NCT07638449","Silkworm Pupa Powder Improves Alzheimer's Disease","A Prospective, Single-Arm Study Evaluating Silkworm Pupa Powder in Improving Alzheimer's Disease Among Patients","Inclusion Criteria:\n\n* Diagnosis of probable Alzheimer's disease (AD) according to the National Institute on Aging-Alzheimer's Association (NIA-AA) criteria. Disease severity is classified as mild to moderate, defined as a Mini-Mental State Examination (MMSE) total score of 0-24 points, inclusive, at both screening and baseline.\n* Confirmation of AD pathology per the 2024 revised AD diagnostic criteria (biomarker-defined AD with both Aβ and tau positivity):\n* Aβ positivity: Plasma Aβ42\u002F40 ratio ≤0.08 or amyloid-PET positivity (SUVR ≥1.1).\n* Tau positivity: Plasma p-tau217 ≥2.5 pg\u002FmL (or CSF p-tau181\u002FAβ42 ratio ≥0.02).\n* Age 50 to 90 years (inclusive), male or female, with at least a primary school education.\n* Stable medication use: If receiving approved AD therapies (e.g., acetylcholinesterase inhibitors, GV-971, NMDA receptor antagonists), doses must remain stable for ≥12 weeks prior to baseline. Treatment-naïve participants are also eligible. All other permitted non-AD related concomitant medications must remain stable for ≥4 weeks prior to baseline unless otherwise specified.\n* Hachinski Ischemia Scale (HIS) total score ≤4.\n* Geriatric Depression Scale-15 (GDS-15) total score ≤4.\n* Neuroimaging evidence: Screening CT\u002FMRI showing age-related brain changes or cerebral atrophy.\n* Participant has a stable and reliable caregiver, as confirmed by the investigator.\n* Written informed consent must be provided by the participant or, if the participant lacks decision-making capacity, by a legally authorized representative (in accordance with local laws, regulations, and customs). Participants must agree to provide peripheral blood, stool, and urine samples during the study for biomarker analysis.\n\nExclusion Criteria:\n\n* Diagnosis of dementia other than Alzheimer's disease (AD) or other central nervous system disorders.\n* Unstable vital signs accompanied by abnormalities in cardiac, pulmonary, hepatic, renal, or other organ functions.\n* Abnormally low folate and\u002For vitamin B12 levels, or evidence that hypothyroidism has caused or exacerbated the participant's dementia. Abnormal syphilis test results.\n* Comorbid psychiatric disorders.\n* Long-term alcoholism or substance abuse that may compromise the evaluation of treatment efficacy.\n* Intolerance or allergy to the study medication (silkworm pupa powder).\n* Abnormalities detected on cranial MRI, including ischemic or hemorrhagic infarctions, hydrocephalus, or brain tumors.\n* Diagnosis of clinically significant cardiovascular or cerebrovascular disease requiring treatment within 12 months or at present.\n* Geriatric Depression Scale-15 (GDS-15) score \\>4 at screening.\n* Any other inadequately controlled condition (e.g., cardiac, respiratory, renal, or gastrointestinal disorders affecting absorption, such as gastric cancer, gastric bypass surgery, or recurrent diarrhea) that may jeopardize participant safety or interfere with study assessments, as judged by the investigator.\n* Administration of any new chemical entity in an AD clinical study within 6 months prior to screening.\n* Clinically significant abnormalities in physical examination, vital signs, laboratory tests, or electrocardiogram (ECG) requiring further investigation, treatment, or posing risks to study procedures or safety.\n* Participation in a clinical study involving therapeutic monoclonal antibodies, antibody-derived proteins, immunoglobulin therapy, or vaccines within 6 months prior to screening.\n* Participation in a clinical study involving any anti-amyloid therapies (including any monoclonal antibody therapy and any BACE inhibitor therapy).\n* Any inadequately controlled immune disorder, or immune disease requiring treatment with immunoglobulins, systemic monoclonal antibodies (or derivatives), systemic immunosuppressants, or plasmapheresis during the study.\n* Inadequately controlled bleeding disorders (including platelet count \\\u003C50,000 or INR \\>1.5 for participants not on anticoagulants, e.g., warfarin). Participants on anticoagulants must have their anticoagulation status optimized and receive a stable dose within 4 weeks prior to screening. Participants receiving anticoagulant therapy must not participate in cerebrospinal fluid (CSF) assessments.\n* Participation in another concurrent silkworm pupa powder intervention study conducted at the same study center.","90 Years",{"count":151,"type":23},[26],"The goal of this clinical trial is to learn if silkworm pupa powder works to treat Alzheimer's disease in patients. It will also learn about the safety of silkworm pupa powder, and its effect on patients' nutritional and frailty status. The main questions it aims to answer are:\n\n* Does silkworm pupa powder improve cognitive function and daily living abilities?\n* Does silkworm pupa powder improve nutritional status and frailty?\n* What medical problems do participants have when taking silkworm pupa powder?\n\nResearchers will evaluate the treatment by comparing the participants' conditions after taking the powder to their baseline conditions (a single-arm study without a placebo) to see if silkworm pupa powder works to treat Alzheimer's disease.\n\nParticipants will:\n\n* Take silkworm pupa powder every day for 12 weeks\n* Visit the clinic once every 4 weeks for checkups and tests\n* Use an electronic punch-card system daily and report any symptoms",[491,29,492,358],"Alzheimer Disease","Asthenia",[494,495,496,497,498],"Silkworm Pupa Powder","Nutritional Status","Frailty State","Cognitive Function","Dietary Supplement",{"date":417,"type":34},{"date":501,"type":23},"2026-06-01",{"date":194,"type":23},{"name":504,"class":41},"Zhejiang Provincial Tongde Hospital",{"id":506,"slug":507,"hasResults":12,"nctId":508,"briefTitle":509,"officialTitle":510,"acronym":511,"eligibilityCriteria":512,"healthyVolunteers":18,"sex":19,"minAge":274,"maxAge":513,"enrollmentInfo":514,"targetDuration":4,"studyType":24,"phases":516,"briefSummary":517,"conditions":518,"keywords":521,"overallStatus":188,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":529,"startDateStruct":531,"completionDateStruct":532,"leadSponsor":534,"locationsCount":264},"100617987","effectiveness-of-a-remind-diet-intervention-on-sarcopenia-cognitive-frailty-and-nutritional-status-in-older-adults-100617987","NCT07325760","Effectiveness of a ReMIND Diet Intervention on Sarcopenia, Cognitive Frailty and Nutritional Status in Older Adults","1. Translating MY-MINDD Into Practice: Retort Meal Interventions to Improve Muscle Health, Nutritional Status, and Food Security Among Malaysian Older Adults 2. Effectiveness of ReMIND Diet- Based Retort Meal Intervention on Cognitive Frailty in Low-Income Malaysian Older Adults: A Cluster Randomised Controlled Trial","ReMIND","Inclusion Criteria:\n\n* Malaysian older adults aged 60 to 84 years.\n* Classified under the B40 income group.\n* Preferably living independently, without receiving daily meals from family members; cohabitation with other older adults is acceptable if meal support is not provided.\n* Experiencing food insecurity as assessed by screening questionnaires.\n* Able to provide informed consent.\n* Participate in the study for the full duration.\n* Able to stand without support.\n* For older adults living with a spouse, preferably both partners must be eligible, willing to participate, and recruited for the study.\n\nExclusion Criteria:\n\n* Individuals with diagnosed terminal illnesses (e.g., cancer, end-stage liver failure, end-stage lung disease, and severe form of heart diseases) and having medical conditions requiring specialized dietary restrictions (e.g., chronic\u002Fend-stage renal disease, severe dysphagia).\n* Those with cognitive impairments or disabilities that prevent them from understanding the study procedures or providing consent.\n* Participants or their spouse enrolled in other nutrition-related intervention programs during the study period.\n* Those unwilling or unable to adhere to the intervention protocol.\n* Bedridden\n* Handicapped or amputated\n* Wearing pacemaker\n* Vegetarian, food allergies or food intolerance","84 Years",{"count":515,"type":23},70,[26],"This research is a single-blinded, 12-week, two-arm cluster randomized controlled trial to evaluate the effectiveness of a Malaysian-adapted MIND (Mediterranean-DASH Intervention for Neurodegenerative Delay) diet retort meal intervention on sarcopenia risk, cognitive frailty status, nutritional status, depression, functional ability, and food security among older adults in Malaysia. With Malaysia projected to become an aged society by 2030, addressing age-related health challenges, including cognitive frailty and sarcopenia, is a national priority. Current evidence indicates that poor diet quality and food insecurity among older adults, especially those in low-income urban communities, exacerbate these conditions. The study is grounded on the Meals on Wheels (MoW) program, which has been effective in reducing malnutrition among older populations globally but is limited in scalability due to high delivery costs. Retort meals which are shelf-stable and nutritionally balanced offer a feasible alternative for meal provision in poor urban settings. The MIND diet, originally designed to support brain health, also demonstrates benefits for muscle health and overall physical function. However, its adaptation to the Malaysian context is crucial due to cultural dietary preferences and cost barriers to certain ingredients. The intervention will recruit 70 older adults (aged 60-84 years) from Program Perumahan Rakyat (PPR) Seri Alam Fasa 2 and Perumahan Awam (PA) Loke Yew in Kuala Lumpur, classified under the B40 income group and at risk of food insecurity. The intervention group will receive retort meals designed according to the adapted MIND diet principles, while the control group will not receive intervention. Data will be collected at baseline, 6 weeks, and 12 weeks to assess outcomes in muscle health, cognitive frailty, nutritional status, depression, functional ability, food security, and cost-effectiveness. Overall, the conceptual framework provides a structured approach to understanding how the intervention contributes to improved nutritional well-being and supports the economic viability of the Meals on Wheels program. Potential confounding variables, including socioeconomic status, baseline health conditions, social support, and lifestyle factors, may also influence the outcomes. Participants will fill up a questionnaire regarding their sociodemographic characteristics, medical factors, psychological factors, lifestyle factors, food security status, functional ability, and depression status. Besides, the researcher will conduct face-to-face interviews to collect data regarding anthropometric measurements, handgrip strength, medical costs, and diet history. Statistical analyses will employ mixed-effects models to evaluate both continuous and categorical outcomes over time. The findings will generate crucial evidence on the feasibility, effectiveness, and cost-efficiency of using retort meals within MoW programs in Malaysia. Furthermore, it will inform national strategies to address food insecurity, promote healthy ageing, and reduce the burden of age-related health conditions. With Malaysia's rapidly ageing population and increasing prevalence of sarcopenia and cognitive frailty, this study has the potential to shape policy and practice by offering a sustainable, culturally tailored nutrition intervention. The evidence derived will support the scaling up of MoW programs using retort meals and contribute to long-term solutions for improving the quality of life and independence of older adults in Malaysia.",[29,519,520],"Cognitive Frailty","Nutritional Interventions",[522,157,523,524,525,526,527,528],"older adults","cognitive","cognitive frailty","malnutrition","mind diet","my-mindd","nutrition intervention",{"date":530,"type":34},"2026-06-05",{"date":292,"type":23},{"date":533,"type":23},"2027-02-26",{"name":535,"class":41},"Universiti Putra Malaysia",{"id":537,"slug":538,"hasResults":12,"nctId":539,"briefTitle":540,"officialTitle":541,"acronym":4,"eligibilityCriteria":542,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":486,"enrollmentInfo":543,"targetDuration":4,"studyType":24,"phases":545,"briefSummary":546,"conditions":547,"keywords":549,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":553,"startDateStruct":554,"completionDateStruct":556,"leadSponsor":557,"locationsCount":42},"100585139","silkworm-pupa-powder-improves-dementia-100585139","NCT06898476","Silkworm Pupa Powder Improves Dementia.","A Prospective, Double-Blind, Randomized Controlled Trial Evaluating Silkworm Pupa Powder Versus Placebo in Improving Alzheimer's Disease Among Patients","Inclusion Criteria:\n\n* Diagnosis of probable Alzheimer's disease (AD) according to the National Institute on Aging-Alzheimer's Association (NIA-AA) criteria, with disease severity classified as mild, moderate, or severe (i.e., Mini-Mental State Examination \\[MMSE\\] total score between 0 and 24 points \\[inclusive\\] at screening and baseline).\n* Confirmation of AD pathology per the 2024 revised AD diagnostic criteria (biomarker-defined AD with both Aβ and tau positivity):\n* Aβ positivity: Plasma Aβ42\u002F40 ratio ≤0.08 or amyloid-PET positivity (SUVR ≥1.1).\n* Tau positivity: Plasma p-tau217 ≥2.5 pg\u002FmL or CSF p-tau181\u002FAβ42 ratio ≥0.02.\n* Age: 50 to 90 years of age (inclusive), with at least a primary school education. Both males and females are eligible.\n* Stable medication use: If receiving approved AD therapies (e.g., acetylcholinesterase inhibitors, GV-971, NMDA receptor antagonists), doses must remain stable for ≥12 weeks prior to baseline. Treatment-naïve participants are also eligible. All other non-AD-related permitted concomitant medications must remain stable for ≥4 weeks prior to baseline unless otherwise specified.\n* Hachinski Ischemia Scale (HIS) total score ≤4.\n* Geriatric Depression Scale-15 (GDS-15) total score ≤4.\n* Neuroimaging evidence: Screening CT\u002FMRI showing age-related brain changes or cerebral atrophy.\n* Caregiver availability: Participant has a stable and reliable caregiver, as confirmed by the investigator.\n* Informed consent: Written informed consent must be provided by the participant or, if the participant lacks decision-making capacity, by a legally authorized representative (in accordance with local laws, regulations, and customs). Participants agree to provide peripheral blood, stool, and urine samples during the study for biomarker analysis.\n\nExclusion Criteria:\n\n* Diagnosis of dementia other than Alzheimer's disease (AD) or other central nervous system disorders.\n* Unstable vital signs accompanied by abnormalities in cardiac, pulmonary, hepatic, renal, or other organ functions.\n* Abnormally low folate and\u002For vitamin B12 levels, or evidence that hypothyroidism has caused or exacerbated the participant's dementia. Participants with abnormal syphilis test results.\n* Patients with comorbid psychiatric disorders.\n* Long-term alcoholism or substance abuse that may compromise the evaluation of treatment efficacy.\n* Participants with intolerance or allergy to the study medications.\n* Abnormalities detected on cranial MRI, including ischemic or hemorrhagic infarctions, hydrocephalus, or brain tumors.\n* Diagnosis of clinically significant cardiovascular or cerebrovascular disease requiring treatment within 12 months or at present.\n* Antibiotic use:\n\n  1. Continuous antibiotic use for more than 10 days within 12 weeks prior to baseline.\n  2. Anticipated need for antibiotic treatment exceeding 10 days during the study.\n* Geriatric Depression Scale-15 (GDS-15) score \\>4 at screening.\n* Any other inadequately controlled condition (e.g., cardiac, respiratory, renal, or gastrointestinal disorders affecting absorption, such as gastric cancer, gastric bypass surgery, or recurrent diarrhea) that may jeopardize participant safety or interfere with study assessments, as judged by the investigator.\n* Participation in any clinical trial involving novel chemical entities for Alzheimer's disease (AD) within 6 months prior to screening, unless confirmed to have been in the placebo group.\n* Clinically significant abnormalities in physical examination, vital signs, laboratory tests, or electrocardiogram (ECG) requiring further investigation, treatment, or posing risks to study procedures\u002Fsafety.\n* Participation in clinical trials involving therapeutic monoclonal antibodies, antibody-derived proteins, immunoglobulin therapy, or vaccines within 6 months prior to screening, unless confirmed to have been in the placebo group.\n* Participation in clinical trials involving anti-amyloid therapies (including monoclonal antibodies or BACE inhibitors), unless confirmed to have received only placebo.\n* Uncontrolled immune disorders requiring treatment with immunoglobulins, systemic monoclonal antibodies (or derivatives), systemic immunosuppressants, or plasmapheresis during the study.\n* Participants with uncontrolled bleeding disorders, including platelet count \\\u003C50,000 or INR \\>1.5 (for those not on anticoagulants, e.g., warfarin). Participants on anticoagulants must have optimized and stable dosing for ≥4 weeks prior to screening. Anticoagulated participants are excluded from cerebrospinal fluid (CSF) assessments.",{"count":544,"type":23},300,[26],"The purpose of this clinical trial is to determine whether silkworm pupa powder is effective in treating Alzheimer's disease. It will also investigate whether silkworm pupa powder can improve the nutritional and frailty status of patients with Dementia. The main questions it aims to answer are:\n\n* Will silkworm pupa powder improve the daily living conditions of patients with Alzheimer's disease?\n* Will silkworm pupa powder improve the nutritional status and frailty of Alzheimer's disease patients?\n\nResearchers will compare silkworm pupa powder with a placebo (a similar substance containing 0.5% silkworm pupa powder) to see if silkworm pupa powder can treat Alzheimer's disease.\n\nParticipants will:\n\n* Take silkworm pupa powder or placebo daily for four months;\n* Visit the clinic for check-ups and tests every four weeks;\n* Record their symptoms and various physiological indicators.",[548,29,492],"Alzheimer Disease(AD)",[491,29,550,551,552],"asthenia","nutritional status","frailty state",{"date":440,"type":34},{"date":555,"type":34},"2025-04-10",{"date":194,"type":23},{"name":504,"class":41},{"id":559,"slug":560,"hasResults":12,"nctId":561,"briefTitle":562,"officialTitle":563,"acronym":4,"eligibilityCriteria":564,"healthyVolunteers":12,"sex":19,"minAge":51,"maxAge":149,"enrollmentInfo":565,"targetDuration":4,"studyType":24,"phases":567,"briefSummary":568,"conditions":569,"keywords":572,"overallStatus":188,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":577,"startDateStruct":578,"completionDateStruct":580,"leadSponsor":582,"locationsCount":4},"100639469","effectiveness-of-combined-glp-1gip-dual-agonist-therapy-and-structured-exercise-on-skeletal-muscle-morphology-quality-and-physical-function-in-overweight-and-obese-individuals-100639469","NCT07609160","Effectiveness of Combined GLP-1\u002FGIP Dual Agonist Therapy and Structured Exercise on Skeletal Muscle Morphology, Quality, and Physical Function in Overweight and Obese Individuals","Effectiveness of Combined GLP-1\u002FGIP Dual Agonist Therapy and Structured Exercise on Skeletal Muscle Morphology, Quality, and Physical Function in Overweight and Obese Individuals: a Randomized Controlled Trial Protocol","Inclusion Criteria:\n\n* initiation of tirzepatide-based pharmacological treatment as prescribed by an endocrinology and metabolism specialist,\n* body mass index (BMI) ≥27 kg\u002Fm² and the presence of a comorbidity condition or BMI≥30 kg\u002Fm²\n* age between 18 and 65 years\n\nExclusion Criteria:\n\n* diagnosis of type 1 or type 2 diabetes mellitus\n* presence of cerebrovascular, hematological, pulmonary, rheumatological, or neurological disorders\n* current participation in a structured diet or exercise program\n* use of weight-loss medications within the past 12 months\n* history of upper or lower extremity surgery or injury within the past 6 months\n* any contraindication to resistance exercise as determined by the treating physician.",{"count":566,"type":23},108,[26],"This randomized controlled trial aims to investigate the effects of a 24-week home-based progressive resistance exercise program combined with tirzepatide treatment on skeletal muscle mass, muscle quality, and functional capacity in overweight and obese individuals. A total of 108 participants initiating tirzepatide therapy will be randomized to either exercise plus pharmacotherapy or pharmacotherapy alone. The primary outcome is change in thigh muscle thickness and echo intensity assessed by ultrasonography.",[570,29,571],"Obesity","Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities",[573,574,575,576],"exercise","physical activity","muscle","physical function",{"date":471,"type":34},{"date":579,"type":23},"2026-11-01",{"date":581,"type":23},"2028-01-01",{"name":583,"class":41},"Acibadem University",{"id":585,"slug":586,"hasResults":12,"nctId":587,"briefTitle":588,"officialTitle":589,"acronym":4,"eligibilityCriteria":590,"healthyVolunteers":18,"sex":19,"minAge":51,"maxAge":4,"enrollmentInfo":591,"targetDuration":4,"studyType":24,"phases":592,"briefSummary":593,"conditions":594,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":595,"lastUpdatePostDateStruct":596,"startDateStruct":597,"completionDateStruct":599,"leadSponsor":600,"locationsCount":42},"100637174","creatine-supplementation-during-glp-1a-therapy-100637174","NCT07625202","Creatine Supplementation During GLP-1a Therapy","A Pilot Study on Creatine Supplementation During Resistance-training for Prevention of Lean Tissue Mass Loss During GLP-1 Receptor Agonist Therapy","Inclusion Criteria:\n\n* Starting GLP-1 agonist therapy\n* 18 years of age or older\n\nExclusion Criteria:\n\n* Positive answers to a screening questionnaire for physical activity safety (the Get Active Questionnaire)",{"count":230,"type":23},[26],"GLP-1 receptor agonists are effective for weight loss, but significant muscle mass is lost as a proportion of this weight loss. This study combines resistance-training and creatine supplementation to try to prevent this loss of muscle mass.",[29],"2026-05-30",{"date":471,"type":34},{"date":598,"type":34},"2026-05-25",{"date":194,"type":23},{"name":601,"class":41},"University of Saskatchewan",{"id":603,"slug":604,"hasResults":12,"nctId":605,"briefTitle":606,"officialTitle":606,"acronym":607,"eligibilityCriteria":608,"healthyVolunteers":18,"sex":19,"minAge":273,"maxAge":609,"enrollmentInfo":610,"targetDuration":4,"studyType":24,"phases":612,"briefSummary":613,"conditions":614,"keywords":618,"overallStatus":188,"whyStopped":4,"lastUpdateSubmitDate":624,"lastUpdatePostDateStruct":625,"startDateStruct":626,"completionDateStruct":628,"leadSponsor":630,"locationsCount":42},"100598718","chrono-restricted-diet-and-physical-activity-as-a-new-preventive-strategy-for-sarcopenia-in-postmenopausal-women-with-obesity-and-type-2-diabetes-100598718","NCT07075133","Chrono-restricted Diet and Physical Activity as a New Preventive Strategy for Sarcopenia in Postmenopausal Women With Obesity and Type 2 Diabetes","TIMEDIAB","Inclusion Criteria:\n\n* Post-menopausal women (amenorrhea for at least 12 months, confirmed by gonadotrophins measures)\n* Age range 45-70 years\n* T2DM diagnosed for more than 1 year\n* Subjects with T2DM treated with lifestyle control alone or associated with metformine ± DPP4 inhibitors\n* Ability to sign written informed consent before any study-specific procedure\n* Subject considered as reliable and capable of adhering to protocol\n* Subjects with Body Mass Index (BMI)≥ 30 kg\u002Fm²\n* Baseline eating period ≥ 14 h per day (as estimated by 95% eating interval)\n\nExclusion Criteria:\n\n* Subjects on T2DM injectable medication or drugs able to induce hypoglycemia (glinides, sulfonylurea)\n* Subjects with HbA1c \\> 8%\n* Subjects with any of the following medical conditions:\n\n  * Congestive cardiac failure\n  * Stage 4 chronic kidney disease (i.e. eGFR \\\u003C 30 ml\u002Fmin\u002F1.73 m2)\n  * Liver cirrhosis or chronic liver disease\n  * Any medical condition that in the opinion of the investigator could jeopardize or compromise the subject's ability to participate in the study\n* Subjects with previous or present history of serious eating disorder\n* Subjects not able to understand the informed consent form or fasting diary instructions\n* Subjects currently participating or has participated in another study of an investigational medication or an investigational medical device within the last 30 days\n* Women with menopause hormone replacement therapy","70 Years",{"count":611,"type":23},45,[26],"The aim of TIMEDIAB is to demonstrate that early TRE (eTRE) combined to late (afternoon) exercise will outperform eTRE combined to morning exercise on muscle function as primary endpoint, and glucose homeostasis as secondary endpoint",[570,29,615,616,617],"Post Menopause","Type 2 Diabetes","Circadian Clock",[619,620,621,622,570,285,623],"Timing of eating","Timing of exercise","Muscle Function","Metabolic Health","women","2026-05-28",{"date":501,"type":34},{"date":627,"type":23},"2026-09-15",{"date":629,"type":23},"2029-07-15",{"name":631,"class":41},"University Hospital, Toulouse",{"id":633,"slug":634,"hasResults":12,"nctId":635,"briefTitle":636,"officialTitle":637,"acronym":4,"eligibilityCriteria":638,"healthyVolunteers":12,"sex":19,"minAge":274,"maxAge":4,"enrollmentInfo":639,"targetDuration":4,"studyType":24,"phases":641,"briefSummary":643,"conditions":644,"keywords":4,"overallStatus":188,"whyStopped":4,"lastUpdateSubmitDate":645,"lastUpdatePostDateStruct":646,"startDateStruct":648,"completionDateStruct":649,"leadSponsor":651,"locationsCount":42},"100638563","phase-2-clinical-study-of-tj0113-capsule-in-the-treatment-of-patients-with-sarcopenia-100638563","NCT07620938","Clinical Study of TJ0113 Capsule in the Treatment of Patients With Sarcopenia","A Randomized, Double-Blind, Multicenter, Placebo Parallel-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of TJ0113 Capsule in the Treatment of Patients With Sarcopenia","Inclusion Criteria:\n\n1. Voluntarily participate in the clinical study and sign the informed consent form (ICF), willing and able to comply with the study protocol (e.g., able to understand and complete questionnaires, adhere to visit schedules, and use study medication);\n2. Male or female aged ≥60 years at the time of signing the ICF;\n3. Meet the diagnostic criteria of the \"Guideline for Diagnosis and Treatment of Sarcopenia in China (2024 Edition)\", specifically as follows:\n\n   3.1Low muscle mass: DXA measurement of muscle mass \\\u003C 7.0 kg\u002Fm2 in males \u002F \\\u003C 5.4 kg\u002Fm2 in females, or BIA measurement of muscle mass \\\u003C 7.0 kg\u002Fm2 in males \u002F \\\u003C 5.7 kg\u002Fm2 in females; 3.2Low muscle strength (grip strength \\\u003C 28.0 kg in males, grip strength \\\u003C 18.0 kg in females); and\u002For physical dysfunction (walking speed in free state \\\u003C 1 m\u002Fs, or 5 Times Sit-to-Stand Test ≥ 12 s, or Short Physical Performance Battery score ≤ 9).\n4. Able to complete the 400-meter Walk Test within 15 minutes without sitting down, leaning against a wall, requiring assistance from others, or using a walker or cane.\n5. Participants of childbearing potential (including spouses of male participants) must have no plans for pregnancy or sperm donation from the screening period until 6 months after the last dose, and must be willing to use at least one effective contraceptive method (see Appendix 1) for contraception.\n6. Results of comprehensive physical examination, vital signs, routine laboratory tests (hematology, blood biochemistry, urinalysis, coagulation), 12-lead ECG, chest X-ray, etc., are normal or, if abnormal, are judged by the investigator to be in the following condition: chronic diseases (e.g., hypertension, hyperlipidemia controlled within normal range, well-controlled non-insulin-dependent diabetes mellitus, etc.) that are judged by the investigator to be stably controlled, with regular medication according to a defined regimen for 4 weeks before screening, and that do not affect the study observation parameters after enrollment; abnormal screening test items judged by the investigator to be related to the participant's age or the aforementioned chronic diseases.\n\nExclusion Criteria:\n\n1. Presence of any medical condition that may interfere with adequate participation in the study, including but not limited to: history of epilepsy or complications, hemolytic anemia, pulmonary embolism or history of malignancy;\n2. Participants who have experienced a New York Heart Association (NYHA) Class III or above congestive heart failure, unstable angina pectoris, acute myocardial infarction, hemorrhagic stroke (stroke), and ischemic stroke (including transient ischemic attack) within 6 months before screening; or those who have undergone any percutaneous coronary intervention or coronary artery bypass grafting, heart valve repair\u002Freplacement; or those with severe arrhythmia as judged by the investigator at the time of screening;\n3. Personal or family history of long QT syndrome, family history of sudden death before the age of 40 in first-degree relatives (parents, children, and siblings); and\u002For personal history of unexplained syncope within 1 year prior to screening; and\u002For based on resting ECG results at screening: QT interval corrected for heart rate using Fridericia's formula, QTcF \\> 450 ms (males), QTcF \\> 470 ms (females) \\[Fridericia's formula: QTc = QT\u002F(RR0.33), where RR represents the standard heart rate value, calculated as 60 divided by heart rate\\];\n4. Presence of uncontrolled hypertension at screening, defined as systolic blood pressure ≥ 160 mmHg and\u002For diastolic blood pressure ≥ 100 mmHg (confirmed before randomization);\n5. Occurrence of chest pain, severe dyspnea, or other safety issues during baseline functional tests (e.g., 400-meter Walk Test);\n6. Presence of clinically significant hepatic impairment, defined as total bilirubin (TBIL) \\> 2 × upper limit of normal (ULN) or alanine aminotransferase (ALT) and\u002For aspartate aminotransferase (AST) \\> 2 × ULN;\n7. Presence of clinically significant renal impairment (creatinine clearance rate \\[Ccr\\] \\\u003C30 mL\u002Fmin). The formula for calculating Ccr is provided in Appendix II;\n8. Suffering from underlying diseases that may cause malnutrition, including chronic diarrhea (defined as a significant increase in bowel movement frequency compared to usual habits \\[\\>3 times\u002Fday\\], lasting \\>4 weeks, or recurrent diarrhea with intervals of 2-4 weeks), Crohn's disease and other digestive system diseases, neuropsychiatric disorders such as anorexia nervosa, uncontrolled diabetes mellitus (fasting blood glucose \\>8.3 mmol\u002FL after treatment) and other metabolic diseases, chronic obstructive pulmonary disease (Modified Medical Research Council Dyspnea Scale \\[MMRC\\] score ≥2), chronic heart failure (diagnosed according to the Chinese Guidelines for the Diagnosis and Treatment of Heart Failure, 2024, NYHA class III or above), and other chronic wasting diseases, which, in the investigator's judgment, make the patient unsuitable for participation in this study;\n9. Use of selective serotonin reuptake inhibitors (e.g., fluoxetine, paroxetine, trazodone, citalopram, escitalopram, etc.) within 4 weeks prior to screening;\n10. Individuals with neuromuscular diseases (e.g., Parkinson's disease), or other muscle system disorders such as muscular atrophy or myositis that could affect the diagnostic parameters of sarcopenia;\n11. Individuals with a cardiac pacemaker or stent implanted in the body, or with metal internal fixation devices, excluding dentures;\n12. Individuals with physical disabilities or injuries\u002Fsurgeries to the upper or lower limbs within the past 3 months that could affect grip strength or gait speed measurements;\n13. Participants with a history of severe allergy, or known hypersensitivity\u002Fallergic reaction or intolerance to any component of the investigational product;\n14. Use of medications affecting musculoskeletal metabolism (bisphosphonates, estrogens, calcitonin, teriparatide, long-term oral or injectable corticosteroids) within 7 days or 5 half-lives before screening, whichever is longer (Note: Participants receiving a stable dose of denosumab for ≥ 6 months before screening and who will not change the dose during the study are allowed to enroll);\n15. Evidence of alcohol abuse (average weekly consumption of ≥ 14 units of alcohol, where 1 unit ≈ 360 mL of beer, or 45 mL of liquor, or 150 mL of wine) or alcohol dependence within 6 months before screening, which in the investigator's opinion would interfere with the participant's understanding or completion of the study;\n16. History of drug dependence\u002Fdrug abuse within the past 1 year;\n17. Positive for hepatitis B surface antigen (HBsAg) with HBV-DNA ≥ 1000 copies\u002FmL or 200 IU\u002FmL, or positive for hepatitis C virus (HCV) antibody with HCV RNA ≥ the lower limit of detection of the study site, or positive for human immunodeficiency virus (HIV) antibody, or positive for Treponema pallidum antibody at screening;\n18. Participation in a clinical study involving administration of an investigational drug, device, or surgery within 3 months or 5 half-lives (whichever is longer) before the first dose;\n19. Inability to swallow oral medications, or, in the investigator's judgment, presence of any condition that could significantly affect drug absorption, distribution, metabolism, or excretion (e.g., active enteropathy, partial or complete intestinal obstruction, chronic diarrhea), or any condition that could pose a risk to the participant;\n20. Participants who have a history of organ transplantation (excluding corneal transplantation);\n21. Blood donation (including blood products) or blood loss ≥ 400 mL, or receipt of blood transfusion (including blood products) within 1 month before screening;\n22. Pregnant or breastfeeding women;\n23. Other reasons deemed by the investigator that the participant has poor compliance or is unsuitable for participation in this study.",{"count":640,"type":23},204,[642],"PHASE2","This study is a randomized, double-blind, multicenter, placebo parallel-controlled Phase II clinical study designed to evaluate the clinical efficacy and safety of TJ0113 Capsule in patients with sarcopenia. The entire study plans to enroll 204 participants with sarcopenia. Eligible participants will be stratified by age (\\\u003C 70 years or ≥ 70 years to ≤ 80 years or \\> 80 years) and block-randomized in a 1:1:1:1 ratio into 4 groups (TJ0113 Capsule 100 mg dose group; TJ0113 Capsule 200 mg dose group; TJ0113 Capsule 400 mg dose group; placebo group), with 51 participants per group. Participants in the placebo group will then be re-randomized in a 1:1:1 ratio to the respective dose groups (100 mg, 200 mg, and 400 mg). After randomization, study participants will receive continuous oral administration for 26 weeks with efficacy and safety evaluations, followed by a 1-week follow-up period after the end of treatment.",[29],"2026-05-27",{"date":647,"type":34},"2026-06-02",{"date":36,"type":23},{"date":650,"type":23},"2027-10-22",{"name":652,"class":79},"Hangzhou PhecdaMed Co., Ltd.",{"id":654,"slug":655,"hasResults":12,"nctId":656,"briefTitle":657,"officialTitle":657,"acronym":658,"eligibilityCriteria":659,"healthyVolunteers":18,"sex":19,"minAge":405,"maxAge":274,"enrollmentInfo":660,"targetDuration":4,"studyType":24,"phases":662,"briefSummary":663,"conditions":664,"keywords":665,"overallStatus":188,"whyStopped":4,"lastUpdateSubmitDate":671,"lastUpdatePostDateStruct":672,"startDateStruct":673,"completionDateStruct":674,"leadSponsor":676,"locationsCount":42},"100640983","osteoporosis-and-sarcopenia-prevention-in-middle-aged-population-100640983","NCT07611097","Osteoporosis and Sarcopenia Prevention in Middle-Aged Population","FORTIFY","Inclusion Criteria:\n\n* General Population: Women and men aged 40-60 years, defined as age groups where the rate of injuries were still relatively lower, thus considered as a low to moderate risk cohort for osteoporosis.\n* Risk profile: Targets a low to moderate risk cohort for osteoporosis (e.g., as defined by no prior fragility fracture and questionnaire). This aligns with the study's primary prevention objective.\n* Individuals with well-controlled comorbidities like hypertension, diabetes, or pre-diabetes can be included in the study program. Exercise and healthy nutritional diets can also help treat their existing health conditions.\n\nExclusion Criteria:\n\n* Significant comorbidities: Individuals with existing (e.g., severe or uncontrolled) medical illness, due to risk to aerobic exercise. This includes, but is not limited to, active ischemic heart disease, unstable angina, uncontrolled hypertension, or other conditions as determined by study physicians.\n* High baseline activity: Individuals who have engaged in \\>4 hours intensive sports per week will be excluded. This population is deemed to be at very low risk, thus would likely derive minimal additional benefit from the intervention, and their inclusion could represent inefficient use of finite resources (e.g., DEXA scanning services).",{"count":661,"type":23},8336,[26],"This initiative is designed to yield substantial and multi-level benefits for the Hong Kong community by pioneering a transformative model of preventive healthcare. It represents the largest randomized controlled trial for osteoporosis and sarcopenia prevention in the region, adopting a comprehensive approach to fracture prevention through innovative fitness, lifestyle, and digital strategies.\n\nThe study's primary objective is to evaluate the efficacy of preventing fractures, osteoporosis, and sarcopenia through an incentivized program of fitness and lifestyle modifications in adults aged 40-60. The secondary objectives include: (1) to validate the use of simple, low-cost measures (grip strength and InBody body composition analysis) as reliable proxy indicators for osteoporosis and sarcopenia risk relative to the gold-standard DEXA scan; (2) to develop a formal, standardized clinical protocol for early detection and prevention, including specified DEXA anatomical measurement sites, for use by healthcare professionals in primary and community care settings; (3) to assess changes in exercise behavior, musculoskeletal health, physical function, health literacy, and participant engagement with the digital (AI chatbot) support system; (4) to analyze the cost-effectiveness of the intervention compared to standard care or pharmacological treatment, including an assessment of healthcare utilization and Quality-Adjusted Life Years (QALYs).\n\nAfter baseline screening and consent, participants are randomly assigned to one of two groups (1:1 ratio) with intention-to-treat principles. The Control Group will receive passive, static support. This involves participating in one initial FUN Day, receiving standard exercise videos, using a passive chatbot for data reporting, undergoing start and end DEXA scans (which require a co-payment), completing a 3-month assessment, and receiving souvenirs at the study start and end. Meanwhile, the Intervention Group will receive active, dynamic support designed to build and reinforce healthy habits. This involves participating in the initial FUN Day, a reinforcement FUN Day at 2 months, nine mandatory structured exercise touchpoints, using an active chatbot with reminders, feedback, and gamification, undergoing start and end DEXA scans (which require a co-payment), completing a 3-month assessment, and receiving ongoing incentives and souvenirs at multiple points. Therefore, researchers will compare between the control and intervention groups to see if intervention can prevent osteoporosis and sarcopenia at a population level.\n\nAll participants will undergo a series of assessments at specific timepoints. This includes two DEXA scans (at the study start and in the fourth year, requiring a participant co-payment), InBody composition analysis, and physical health assessments (e.g., grip strength, balance, cardiovascular fitness). These assessments will be performed at baseline (during the first FUN Day), 3 months, 12 months, 24 months, and 36 months. A long-term follow-up will continue for up to 10 years to monitor adverse health events such as falls and fractures. Participants will also complete questionnaires via an AI chatbot at baseline, 3 months, and annually during follow-up. The collected data will encompass health literacy (e.g., osteoporosis\u002Fsarcopenia knowledge scores), digital engagement (e.g., chatbot responsiveness), and economic outcomes (e.g., incremental cost per Quality-Adjusted Life Year \\[QALY\\] gained). Data analysis will employ appropriate statistical methods to compare outcomes between the control and intervention groups across all assessments and timepoints.",[94,29],[470,666,667,668,669,670],"Middle-Aged Population","Osteoporosis Prevention","Sarcopenia Prevention","AI Chatbot","DEXA Alternative","2026-05-20",{"date":624,"type":34},{"date":501,"type":23},{"date":675,"type":23},"2036-05-31",{"name":677,"class":41},"The University of Hong Kong"]